Мотилак (Domperidone) is generally used to provide supportive symptomatic relief by addressing certain distressing symptoms associated with compromised upper gastrointestinal function. It is applied across domains where additional symptomatic support is needed to help manage discomfort and functional strain.

1. Relief for Nausea and Vomiting Episodes

The medication is applied in addressing nausea and vomiting caused by certain systemic medications. This domain is relevant in contexts involving acute or chronic manifestations of nausea and vomiting.

2. Management of Dyspepsia and Post-Meal Discomfort

This medication is considered relevant in conditions characterized by periods of heightened symptoms of functional dyspepsia, and may assist with managing symptom clusters that may become intense or disruptive, such as a premature feeling of fullness (early satiety), persistent bloating, and stomach discomfort after eating. It contributes to easing the overall symptom load and provides supportive relief when symptoms interfere with routine activities. The medication is commonly used across conditions presenting with symptoms linked to gastroparesis, functional dyspepsia, and nausea linked to certain drug therapies.

“The medication provides support that helps ease the overall symptom burden during episodes of heightened discomfort.”

Quick Fact: Relief for Post-Meal Heaviness This medication is applied in addressing symptoms that create noticeable physiological strain, and may assist with maintaining functional stability.

The eligibility profile for Мотилак (Domperidone) is defined by strict regulatory constraints focusing on cardiovascular health and age-specific safety, as established by major health authorities. Use is authorized for adults and adolescents 12 years of age or older weighing 35 kg or more.

The medicine is contraindicated in several populations and must not be used by individuals with:

• Underlying cardiac conditions, including pre-existing QTc prolongation, congestive heart failure, or significant electrolyte disturbances.
• Moderate or severe hepatic impairment (liver function).
• Gastrointestinal structural issues such as hemorrhage, mechanical obstruction, or perforation.
• Prolactin-releasing pituitary tumour (prolactinoma).
• Co-administration of potent CYP3A4 inhibitors or QT-prolonging medicines.

Age Group	Eligibility Status
Children < 12 years	No longer licensed (lack of established efficacy).
Adults > 60 years	Use is cautioned (increased cardiac risk).

Additionally, use is not recommended during pregnancy or breastfeeding. Patients with severe renal impairment require a specific reduction in dosing frequency, representing conditional eligibility.

Interactions with other medicines and products

The interaction profile for Мотилак (Domperidone) defines mandatory constraints based on the risk of increased drug exposure and additive cardiac effects, as documented by regulatory authorities.

Interaction Category	Regulatory Statement
Contraindicated Combinations	Co-administration is formally prohibited with potent CYP3A4 inhibitors (e.g., systemic azole antifungals, certain macrolides, HIV protease inhibitors) and all medicines known to prolong the QTc interval (pharmacodynamic risk).
Pharmacokinetic Basis	Domperidone is primarily cleared via the CYP3A4 enzyme. Inhibition of this enzyme leads to significantly increased domperidone plasma concentrations and reduced clearance.
Timing Requirement	Antacids and Antisecretory Agents must not be taken simultaneously, as reduced gastric acidity officially impairs absorption and lowers bioavailability.

Population-Specific Restrictions: The interaction-related cardiac risks are officially noted as heightened in patients older than 60 years and those taking doses greater than 30 mg daily. The medicine is contraindicated in patients with significant electrolyte disturbances or moderate to severe hepatic impairment, as these conditions increase the risk of accumulation and proarrhythmia associated with drug interactions.

Connection to the overall interaction profile: Regulatory documents structure the product's use around the prohibition of substances that interfere with its primary metabolism or exacerbate its known cardiac effects. This framework dictates strict restrictions on co-administration to mitigate pharmacokinetic accumulation and pharmacodynamic cardiac risk.

Мотилак (domperidone) acts as a selective antagonist (blocker) of dopamine D2 receptors; this interaction modulates signaling patterns at two primary locations.

Targeting Dopamine Receptors to Enhance Gastrointestinal Motility

This domain covers the drug's interaction with D2 receptors in the wall of the upper digestive tract. Blocking these peripheral receptors removes the inhibitory effect that dopamine naturally places on muscle contraction, initiating a mechanistic cascade that enhances the release of the neurotransmitter acetylcholine. This interaction modulates GI muscle activity, resulting in accelerated gastric emptying and more coordinated movement through the small intestine—a distinct prokinetic action.

Targeting the Emetic Reflex Pathway for an Antiemetic Effect

This domain involves the drug's interaction with D2 receptors located in the Chemoreceptor Trigger Zone (CTZ), a small area of the brain that controls the vomiting reflex and lies outside the main blood-brain barrier. By engaging these mechanisms, the drug modulates signaling patterns that initiate the emetic reflex. This blockade results in a raised activation threshold of the vomiting center, which is the key mechanism behind the resulting antiemetic physiological effect.

How to Use Мотилак — Official Administration Guidelines

The usage of Domperidone (Мотилак) is governed by protocols focused on administration timing, dose limitation, and short treatment duration. The approved route of administration includes oral forms (tablets, suspension) and rectal forms (suppositories) in regions where available.

Standard Dosing and Timing Protocols

The standard oral dosing for adults and adolescents weighing 35 kg or more is 10 mg per dose, with the maximum daily dose capped at 30 mg. The medicine is typically taken up to three times per day (TID). For optimal absorption, the dose is recommended to be administered 15–30 minutes before a meal, as food intake delays the process. Use over time is strictly limited; treatment duration for acute symptoms must not exceed seven consecutive days. If a dose is missed, standard guidelines specify that the dose must be omitted, and the patient should resume the next scheduled dose without doubling the quantity.

Population-Specific Use and Procedural Constraints

Special conditions apply to certain patient populations. For children weighing less than 35 kg, dosing is based on weight, calculated at 0.25 mg/kg per dose, using the oral suspension. Dose frequency requires modification for patients with severe renal impairment, where administration must be reduced to once or twice daily. Conversely, the medicine is excluded from use in patients diagnosed with moderate to severe hepatic impairment. When using the oral suspension, a suitable measuring device must be employed to ensure the correct amount is delivered.

Research evidence / Overview of Studies for Мотилак

Evidence for Use in Short-Term Nausea and Vomiting

Research examining Мотилак for nausea and vomiting primarily involves short-term Randomized Controlled Trials (RCTs) against a placebo, often over periods of up to one week. These studies monitored outcomes related to episodic or acute changes in symptom frequency and intensity in adults and adolescents (aged 12 years and older). Findings describe patterns observed in these studies, contributing to the broader evidence landscape supporting its study for short-term symptomatic relief. However, the evidence is generally confined to these brief treatment durations, and research has not established sufficient data for children under 12 years with acute gastroenteritis.

---

Evidence for Supportive Relief in Functional Dyspepsia

The research exploring Мотилак and its association with supportive symptom patterns in functional dyspepsia includes systematic reviews and older placebo-controlled RCTs in adult populations. Studies monitored outcomes related to patient-reported perceived discomfort, such as post-meal fullness (early satiety) and bloating, over intermediate periods, usually 4 to 6 weeks. The certainty remains low for this indication, as the evidence base relies on older trials and subjective endpoints. Long-term effects are not fully established, and follow-up durations were limited.

---

Key Research Gaps and Limitations

Evidence has focused primarily on adults, with data for children under 12 years remaining insufficient for acute gastroenteritis. A major research limitation is that the evidence for all indications is generally restricted to short-term findings. Sample sizes were modest in some research scenarios, and comparative evidence against a broad range of alternative treatments is sometimes lacking. Data for certain groups remain insufficient, particularly for long-term use, and research provides context but not individual predictions.

Key Studies & References

1. Domperidone for nausea and vomiting: lack of efficacy in children; reminder of contraindications in adults and adolescents - GOV.UK Drug Safety Update
2. Safety and Efficacy of Low-dose Domperidone for Treating Nausea and Vomiting Due to Acute Gastroenteritis in Children (2019 RCT)

Common questions about Мотилак (FAQ)

Q: What is the main reason doctors prescribe Мотилак?

Official product information describes the main use of the active ingredient in Мотилак as being for the relief of symptoms related to nausea and vomiting. It is categorized as a prokinetic agent, meaning it helps with the movement of food through the digestive tract. Some evidence has also examined its role in providing supportive relief for symptoms associated with delayed gastric emptying.

Q: How quickly can one expect to notice the effects of Мотилак?

Studies focusing on pharmacokinetics—how the body processes the drug—indicate that when the drug is taken while fasting, it is rapidly absorbed. Peak concentrations in the blood plasma are generally reached within 30 to 60 minutes after taking an oral dose.

Q: Are there any common food or drink items that should be avoided when using Мотилак?

Regulatory information describes that combining the drug with grapefruit or grapefruit juice is not recommended. The reason for this is that grapefruit products can increase the amount of the drug in the blood, which may raise the risk of experiencing adverse effects.

Q: Can Мотилак be crushed or split if a person has difficulty swallowing?

Official administration guidance describes the tablets as needing to be swallowed whole with a drink of water. Altering the tablets (crushing, splitting, or chewing) is not recommended, as doing so can interfere with the way the medicine is intended to be absorbed by the body.

Q: Can people with lactose intolerance safely use Мотилак?

The film-coated tablets often contain lactose monohydrate as an inactive ingredient. Regulatory documents state that use is contraindicated in individuals with rare hereditary conditions such as total lactase deficiency or galactose intolerance.

Q: Is Мотилак a medicine that can be used 'as needed'?

The drug is typically limited to short-term use, even when taken on an as-needed basis for acute symptoms. Official protocols describe that the drug’s use is limited to the lowest effective dose for the shortest duration necessary. This generally corresponds to a duration not exceeding one week of consecutive treatment for acute symptoms.

Q: What is the intended duration of the effect after a single dose of Мотилак?

Based on pharmacokinetic studies in healthy individuals, the drug’s elimination half-life is estimated to be approximately 7 to 9 hours. The half-life refers to the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Does Мотилак affect the absorption of other oral medications?

Because Мотилак acts as a gastro-prokinetic agent—meaning it speeds up stomach emptying—it has the potential to influence the absorption rates of other medications taken by mouth at the same time. This is especially relevant for other drugs designed as sustained-release or enteric-coated formulations.

Q: What is the evidence that Мотилак is absorbed efficiently by the body?

The medicine is known to be absorbed rapidly and almost completely after oral administration. However, due to the way the body processes the drug in the gut wall and liver (known as first-pass metabolism), the amount that ultimately reaches the bloodstream (absolute bioavailability) is relatively low, typically around 15%.

Q: Does Мотилак affect bowel movements?

As a gastro-prokinetic agent, the drug is designed to affect movement within the digestive tract. Diarrhoea is listed in the official safety documents as an uncommon side effect, meaning it may affect up to 1 in 100 users.

Q: What should a person do if they suspect an allergic reaction to Мотилак?

Known hypersensitivity (allergy) to the active ingredient is a formal contraindication. Serious allergic-type reactions, such as Angioedema (swelling) or Urticaria (hives), are listed as very rare side effects. Official guidance describes that when signs of hypersensitivity occur, the drug's use is to be discontinued.

Q: Is it considered normal to feel a bit light-headed after taking Мотилак?

Dizziness is listed in the official safety profile as a very rare side effect, and drowsiness is listed as an uncommon side effect. Regulatory guidance describes that caution is recommended if an individual experiences central nervous system effects, especially when engaging in activities like driving or operating tools.

How to Store and Dispose of Мотилак

The official requirements for storing Мотилак (domperidone) focus on maintaining its stability and ensuring safety. The product must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and the temperature must not exceed 30 C. The medicine must be kept in its original container, tightly closed, and protected from light and moisture. Do not refrigerate or freeze Мотилак, as these conditions compromise its stability.

Child Safety and Disposal

The product must be stored out of the sight and reach of children (store locked up). Disposal of unused or expired medicine must follow local regulations, which typically require returning it to a pharmacist or an approved waste disposal plant. The product must not be allowed to enter drains, sewers, or ground water.